Search Results 151-160 of 23015 for Phase

1. A Phase I Study of MSB2311 in Advanced Solid Tumors - Mayo Clinic

   This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended ...

2. Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes - Mayo Clinic

   Phase I: To investigate maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, exploratory biomarker and efficacy of BI 836858 monotherapy in ...

3. A Master Protocol To Evaluate The Long-Term Safety Of (LY3527727) Pirtobrutinib - Mayo Clinic

   Study phase. 4. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase ...

4. A Global Phase III Study Of Rilvegostomig Or Pembrolizumab Plus Chemotherapy For First-Line Treatment Of Metastatic Non-squamous NSCLC - Mayo Clinic

   A Global Phase III Study Of Rilvegostomig Or Pembrolizumab Plus Chemotherapy For First-Line Treatment Of Metastatic Non-squamous NSCLC · More about research at ...

5. Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies - Mayo Clinic

   Phase 2 (stage 1): To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the ...

6. Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk Myelodysplastic Syndromes - Mayo Clinic

   Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules. Participation eligibility. Participant eligibility includes age, gender, type ...

7. A Phase 1 Proof-of-Concept Clinical Trial Evaluating the Safety and Tolerability of Midodrine in Hepatopulmonary Syndrome

   A Phase 1 Proof-of-Concept Clinical Trial Evaluating the Safety and Tolerability of Midodrine in Hepatopulmonary Syndrome · Overview · Participation eligibility.

8. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

   A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors. Print details. Share; Facebook · Twitter.

9. Phase 3 Study Of T-DXd And Rilvegostomig Versus SoC In Advanced HER2-expressing Biliary Tract Cancer - Mayo Clinic

   The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and ...

10. Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) - Mayo Clinic

    Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) · Overview · Participation eligibility · Participating ...